Clinical

Naiyer A. Rizvi, MD, director of thoracic oncology and immunotherapeutics at Columbia University Medical Center discusses the effectiveness of PD-1 antibodies in lung cancer.

A new study highlights how the beliefs of surgeons and radiation oncologists influences radiotherapy use in early-stage breast cancer among older women.

The American College of Cardiology (ACC) is entering into novel digital health partnerships to innovate cardiology care and improve cardiovascular health, explained John Rumsfeld, MD, PhD, chief innovation officer at the ACC.

A recent survey by The Leukemia & Lymphoma Society found that the majority of adults are surprised by the prevalence of blood cancers-specifically the prevalence of acute lymphocytic leukemia among children and young adults.

A new study in the journal BMJ concludes that most oncology drugs approved by the European Medicines Agency between 2009 and 2013 failed to display a benefit on survival or quality of life, even at 3.3 years following market entry.

A research study conducted in a mouse mammary cancer model has found that optimal timing, based on sequencing of immunotherapy agents, is important for treatment efficacy.

A new survey conducted by The Health Management Academy has identified a rapid investment by leading healthcare systems in precision medicine programs, with significant expectations of the impact of real-world outcomes on physician decision making.

Current drugs for pulmonary hypertension treat 3 pathways, but currently there aren't any new drugs to treat different pathways, although there likely will be some in the future, said Simon Gibbs, MD, Reader in Pulmonary Hypertension at the National Heart and Lung Institute, Imperial College London.

Individuals who develop neutropenia are at higher risk of infection, and they should understand the symptoms to look for that might mean they need to seek urgent medical care, explained Ruben A. Mesa, MD, of the Mayo Clinic.

Intuniv, a once-daily non-stimulant from Shire and Shionogi for adults with attention-deficit/hyperactivity disorder, met its primary endpoint and showed a superior change from baseline compared with placebo in a phase 3 study.

October is breast cancer awareness month, and as September ended, a new treatment received the FDA’s approval for advanced breast cancer and another was granted priority review for the adjuvant treatment of early breast cancer.

Skin conditions affect millions of Americans, but patients who seek treatment for their skin condition often face the difficulty of finding an available specialist in their area, according to a new paper published by Derma Care Access Network.

There is an ongoing debate about how aggressively to lower low-density lipoprotein (LDL) cholesterol, but Steve Nissen, MD, of Cleveland Clinic, argues that studies have shown an aggressive approach to lowering LDL always shows benefits.

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

Key lessons learnt at the National Comprehensive Cancer Network's policy meeting: Redefining Quality Measurement in Oncology.

This week, the top managed care stories included the end of the latest attempt to repeal the Affordable Care Act; a call to better include the patient's voice in cancer quality metrics; and an argument for caution regarding the newly approved CAR T-cell therapy, Kymriah.

Combining positron emission tomography and computed tomography early in the treatment plan for patients diagnosed with advanced melanoma can help identify the potential benefit of a specific immunotherapy and avoid the risk of non-beneficial intervention.

John Eikelboom, MD, of McMaster University discusses the 3 arms of the COMPASS trial and explains the need for it to end earlier than anticipated.

A new extended release oral suspension for the treatment of attention-deficit/hyperactivity disorder in patients 6 or older was approved by the FDA and would provide an option for patients seeking a liquid treatment instead of a pill or capsule. Michael Feld, MD, a child, adolescent, and adult psychiatrist in the Chicago area specializing in the treatment of ADHD, explained what the benefits of Adzenys ER from Neos Therapeutics are for both patients and physicians.

Advancements in the cancer immunotherapy pipeline are leading to the production of immune checkpoint inhibitors, and a recent report from Global Business Intelligence (GBI) Research titled “Cancer Immunotherapies-First-in-Class Pipeline Dominated by Immunomodulators and PD-1 Like Targets” took a look at the pipeline.

Adults with moderate-to-severe atopic dermatitis who were treated with Dupixent (dupilumab) from Sanofi and Regeneron along with topical corticosteroids experienced improvements in overall disease severity, according to results from phase 3 of the CAFÉ trial.

Researchers at the London School of Economics and Political Science have developed a multiple criteria decision analysis model, The Advance Value Framework, that payers can utilize for evaluating new medicines that come to the market.

The increasing trend in long-term prescription opioid use in the United States calls for further research on the potential benefits and harm, according to a study.